Bay Area's Arcus Biosciences Scores $107M, Initiates Two Clinical Trials Post author:Sam Post published:November 12, 2017 Post category:BioPharma Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing. Source: BioSpace You Might Also Like Voyager Therapeutic's Parkinson's Trial Shows Positive Results March 8, 2018 71% of ALL Patients Achieved Complete Tumor Remission on Gilead, Kite's CAR-T Therapy December 11, 2017 Maryland's Precision Medicine Group Lands $275M December 26, 2017
71% of ALL Patients Achieved Complete Tumor Remission on Gilead, Kite's CAR-T Therapy December 11, 2017